Neoplasms of the prostate

Bostwick, David G.; Meiers, Isabelle

doi:10.1016/b978-0-323-01970-5.50011-7

Cited by 24 publications

(32 citation statements)

References 1,074 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High-grade prostatic intraepithelial neoplasia (PIN) is the precursor lesion of prostate cancer in most cases, especially cancer arising in PZ, although this relationship appears less certain for cancer originating in the transition and anterior zones [30,[56][57][58][59]. Like prostatic carcinoma, it has also been commonly found to be multifocal [60].…”

Section: Genetic Basis Of Tumor Multiclonality and Aggressivenessmentioning

confidence: 97%

Multifocal prostate cancer: biologic, prognostic, and therapeutic implications

2010

View full text Add to dashboard Cite

Section: Genetic Basis Of Tumor Multiclonality and Aggressivenessmentioning

confidence: 97%

Multifocal prostate cancer: biologic, prognostic, and therapeutic implications

2010

View full text Add to dashboard Cite

“…Prostatic stromal sarcoma is a rare tumor that constitutes approximately 0.1–0.2% of all prostatic cancers [1,2]. Prostatic mesenchymal tumors sometimes cannot be clearly classified as histological entities due to their rarity [5].…”

Section: Discussionmentioning

confidence: 99%

“…Prostatic stromal sarcoma (PSS) is a fairly rare tumor, constituting approximately 0.1% of all prostatic cancers [1,2]. Prostatic sarcoma and related proliferative lesions, including prostatic phyllodes tumors, have been classified as prostatic stromal tumors of uncertain malignant potential (STUMP) and prostatic stromal sarcoma (PSS) based on cellularity, mitotic index, cellular atypia and necrosis (WHO 2004) [3].…”

Section: Introductionmentioning

confidence: 99%

Prostatic stromal sarcoma with neuroectodermal differentiation

et al. 2012

View full text Add to dashboard Cite

Prostatic stromal sarcoma is a fairly rare tumor that constitutes approximately 0.1–0.2% of all prostatic cancers. Detailed characteristics of the tumor are still unclear due to its rarity.We describe a case of prostatic stromal sarcoma in a 63 year-old man who suffered from urinary obstructive symptoms. Palliative transuterine resection was performed and the preliminary histopathological diagnosis was neuroendocrine carcinoma. After chemotherapy, total pelvic exenteration was performed. Histopathologically, the tumor was composed of monotonously proliferating small to medium-sized round cells, which existed in compact islands with loose or dense fibrovascular networks. Immunohistochemically, the tumor cells were widely positive for vimentin, CD56, CD99 and focally positive for synaptophysin, CD10, progesterone receptor, desmin and CD34, but negative for EMA, cytokeratin, estrogen receptor, S-100 and myoglobin. Most of the previously reported tumors exhibited positive stainability for CD10 and progesterone receptor. In addition to these markers, expressions of CD56, CD99 and synaptophysin were characteristically detected in our case. To the best of our knowledge, we present the first case of prostatic stromal sarcoma with characteristic immunohistochemical staining properties. Although the biological characteristics of this rare tumor have not yet been elucidated, these findings suggest prostatic stromal sarcoma can potentially show neuroectodermal differentiation.Virtual slideThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7291874028051262

show abstract

“…Whereas some studies associate NE differentiation with worse prognosis, 11 others do not recognize this as an independent factor in survival, 12 and in fact, earlier studies do not show an apparent correlation between the number of NE cells in prostatic intraepithelial neoplasia/cancer and a variety of clinicopathologic parameters of cancer. 17 14 In addition to the morphologically inconspicuous NE cells, occasionally these cells show abundant granular cytoplasm and bland nuclei, histologically resembling Paneth cells of the gastrointestinal tract.…”

Section: Prostate Cancer With Focal Ne Differentiationmentioning

confidence: 99%

Neuroendocrine Tumors of the Prostate

Rezaei¹

2014

Pathology Case Reviews

View full text Add to dashboard Cite

Prostate cancer, with an estimated 233,000 new cases and 29,480 deaths in 2014, is the most common malignancy among men in the United States and only second to lung cancer as the cause of cancerrelated deaths (CA Cancer J Clin 2014;64:9Y29). While conventional (acinar) adenocarcinoma constitutes the vast majority of prostate cancers, rare variants including neuroendocrine tumors have been recognized by the World Health Organization (World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004) and the American Joint Commission on Cancer (The AJCC Staging Manual. 7th ed. New York: Springer; 2007). Statistically speaking, when an unusual histologic pattern is encountered, one should always consider the possibility of direct extension from adjacent organs and/or metastasis from distant sites. In this article, a brief presentation of 2 cases is followed by an overall review of the spectrum of neuroendocrine tumors of the prostate.

show abstract

Neoplasms of the prostate

Cited by 24 publications

References 1,074 publications

Multifocal prostate cancer: biologic, prognostic, and therapeutic implications

Multifocal prostate cancer: biologic, prognostic, and therapeutic implications

Prostatic stromal sarcoma with neuroectodermal differentiation

Neuroendocrine Tumors of the Prostate

Contact Info

Product

Resources

About